The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure
This study was designed to evaluate the effects of DS37001789, a novel and highly potent urotensin II (U-II) receptor (GPR14) antagonist, against mortality, hypertrophy, and cardiac dysfunction in pressure-overload hypertrophy by transverse aortic constriction (TAC) in mice. In addition, we analyzed...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-02-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844020301973 |
| _version_ | 1818991370561388544 |
|---|---|
| author | Mina Nishi Hideki Tagawa Masumi Ueno Shinji Marumoto Takahiro Nagayama |
| author_facet | Mina Nishi Hideki Tagawa Masumi Ueno Shinji Marumoto Takahiro Nagayama |
| author_sort | Mina Nishi |
| collection | DOAJ |
| description | This study was designed to evaluate the effects of DS37001789, a novel and highly potent urotensin II (U-II) receptor (GPR14) antagonist, against mortality, hypertrophy, and cardiac dysfunction in pressure-overload hypertrophy by transverse aortic constriction (TAC) in mice. In addition, we analyzed the phenotype of GPR14 knockout (KO) mice after TAC induction to confirm the contribution of the U-II/GPR14 system. The oral administration of 0.2% DS37001789 to TAC mice for 12 weeks significantly ameliorated the mortality rate and 0.2% DS37001789 for 4 weeks significantly improved cardiac function by pressure-volume analysis. GPR14 expression was significantly upregulated in the left ventricle in the TAC mice treated with 0.2% DS37001789. Moreover, we confirmed that the significant amelioration of mortality was accomplished by the inhibition of cardiac enlargement and the improvement of cardiac function in GPR14 KO mice after TAC surgery. These results suggest that the U-II/GPR14 system contributes to the progression of heart failure and its blockade ameliorates the mortality via improved cardiac function. The U-II/GPR14 system may thus be an attractive target for treating heart failure with pathological cardiac hypertrophy and DS37001789 may be a novel therapeutic agent for heart failure in patients with pressure-overload conditions such as hypertension and aortic valve stenosis. |
| first_indexed | 2024-12-20T20:09:11Z |
| format | Article |
| id | doaj.art-b695d1a7e136444db47158dfa809205b |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-12-20T20:09:11Z |
| publishDate | 2020-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-b695d1a7e136444db47158dfa809205b2022-12-21T19:27:51ZengElsevierHeliyon2405-84402020-02-0162e03352The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failureMina Nishi0Hideki Tagawa1Masumi Ueno2Shinji Marumoto3Takahiro Nagayama4Specialty Medicine Research Laboratories II, Daiichi-Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan; Corresponding author.Daiichi Sankyo Pharma Development, Daiichi-Sankyo, Inc., 211 Mt. Airy Road, Basking Ridge, NJ 07920, USASpecialty Medicine Research Laboratories I, Daiichi-Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, JapanOrganic Synthesis Department, Daiichi-Sankyo RD Novare Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, JapanBusiness Development & Licensing Department, Daiichi-Sankyo Co., Ltd., 3-5-1 Nihombashihoncho, Chuo-ku, Tokyo 103-8426, JapanThis study was designed to evaluate the effects of DS37001789, a novel and highly potent urotensin II (U-II) receptor (GPR14) antagonist, against mortality, hypertrophy, and cardiac dysfunction in pressure-overload hypertrophy by transverse aortic constriction (TAC) in mice. In addition, we analyzed the phenotype of GPR14 knockout (KO) mice after TAC induction to confirm the contribution of the U-II/GPR14 system. The oral administration of 0.2% DS37001789 to TAC mice for 12 weeks significantly ameliorated the mortality rate and 0.2% DS37001789 for 4 weeks significantly improved cardiac function by pressure-volume analysis. GPR14 expression was significantly upregulated in the left ventricle in the TAC mice treated with 0.2% DS37001789. Moreover, we confirmed that the significant amelioration of mortality was accomplished by the inhibition of cardiac enlargement and the improvement of cardiac function in GPR14 KO mice after TAC surgery. These results suggest that the U-II/GPR14 system contributes to the progression of heart failure and its blockade ameliorates the mortality via improved cardiac function. The U-II/GPR14 system may thus be an attractive target for treating heart failure with pathological cardiac hypertrophy and DS37001789 may be a novel therapeutic agent for heart failure in patients with pressure-overload conditions such as hypertension and aortic valve stenosis.http://www.sciencedirect.com/science/article/pii/S2405844020301973Urotensin IIGPR14Heart failureTransverse aortic constrictionBiological sciencesEndocrinology |
| spellingShingle | Mina Nishi Hideki Tagawa Masumi Ueno Shinji Marumoto Takahiro Nagayama The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure Heliyon Urotensin II GPR14 Heart failure Transverse aortic constriction Biological sciences Endocrinology |
| title | The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure |
| title_full | The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure |
| title_fullStr | The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure |
| title_full_unstemmed | The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure |
| title_short | The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure |
| title_sort | urotensin ii receptor antagonist ds37001789 ameliorates mortality in pressure overload mice with heart failure |
| topic | Urotensin II GPR14 Heart failure Transverse aortic constriction Biological sciences Endocrinology |
| url | http://www.sciencedirect.com/science/article/pii/S2405844020301973 |
| work_keys_str_mv | AT minanishi theurotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure AT hidekitagawa theurotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure AT masumiueno theurotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure AT shinjimarumoto theurotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure AT takahironagayama theurotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure AT minanishi urotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure AT hidekitagawa urotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure AT masumiueno urotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure AT shinjimarumoto urotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure AT takahironagayama urotensiniireceptorantagonistds37001789amelioratesmortalityinpressureoverloadmicewithheartfailure |